Compare CYN & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYN | MDXH |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | Belgium |
| Employees | 62 | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 21.1M |
| IPO Year | 2021 | 2021 |
| Metric | CYN | MDXH |
|---|---|---|
| Price | $1.15 | $0.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 237.8K | ★ 786.3K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $368,138.00 | N/A |
| Revenue This Year | $3,359.28 | $30.78 |
| Revenue Next Year | $347.47 | $18.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.10 | $0.40 |
| 52 Week High | $10.04 | $5.33 |
| Indicator | CYN | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 38.14 | 31.12 |
| Support Level | $1.10 | N/A |
| Resistance Level | $1.40 | $3.79 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 8.33 | 15.36 |
Cyngn Inc is an industrial autonomous vehicle technology company, focused on addressing industrial uses for autonomous vehicles. It develops full-stack autonomous driving software, DriveMod, which is integrated into vehicles manufactured by original equipment manufacturers during the assembly process. The company designs its software to be compatible with a range of sensors and hardware components and integrates it with its own systems to enable autonomous vehicle functionality.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.